Form 4: Fractyl Health CEO Exercises Stock Options, Sells Shares for Tax Purposes

Fractyl Health's CEO, Harith Rajagopalan, exercised stock options and sold shares to cover tax obligations.

Summary

• Fractyl Health's CEO, Harith Rajagopalan, exercised 216,924 restricted stock units on November 10, 2024.
• These restricted stock units vested in full on that date and represent a contingent right to receive one share of common stock each.
• Following the vesting, Mr. Rajagopalan sold 96,517 shares on November 11, 2024, at a price of $2.4696 per share.
• The sale was conducted to cover tax withholding obligations related to the vesting of the restricted stock units.
• After these transactions, Mr. Rajagopalan directly owns 491,329 shares of common stock.
• He also indirectly owns 292,171 shares through a 2021 Irrevocable Trust, 292,170 shares through a 2016 Irrevocable Trust, and 18,639 shares through a 2021 Family Trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the standard practice of executives exercising stock options and selling shares to cover tax liabilities.

Comparison to Industry Standards

• The vesting and subsequent sale of shares by the CEO is a common practice in publicly traded companies, particularly in the biotech sector where stock options are a significant part of executive compensation.
• Similar transactions are regularly reported by executives at comparable companies such as Reata Pharmaceuticals, Madrigal Pharmaceuticals, and Viking Therapeutics.
• These companies also use stock-based compensation as a key component of their executive pay packages, and their executives often sell shares to cover tax obligations after vesting.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small volume of shares sold compared to the total outstanding shares.
• The transaction is a normal part of executive compensation and is not expected to have a material impact on other stakeholders.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, share sale, tax withholding, beneficial ownership, Fractyl Health